| abstract |
The application provides methods of using FXR agonists, in particular, compounds of formula (I), stereoisomers, enantiomers, pharmaceutically acceptable salts, or amino acid conjugates thereof, in the manufacture of compounds for the treatment or prevention of Use in the medicament of a farnesoid X receptor (FXR) mediated disorder, eg, liver disease or gastrointestinal disease, wherein the compound is administered in a dose ranging from about 3 μg to about 100 μg. The application also provides pharmaceutical unit dosage form compositions comprising about 10 μg, about 30 μg, about 60 μg or about 90 μg of Compound A suitable for oral administration at a maximum total dose of up to 100 μg per day. |